1. Home
  2. PRTC vs FTRE Comparison

PRTC vs FTRE Comparison

Compare PRTC & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • FTRE
  • Stock Information
  • Founded
  • PRTC 2015
  • FTRE 1996
  • Country
  • PRTC United States
  • FTRE United States
  • Employees
  • PRTC N/A
  • FTRE N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • FTRE Medical Specialities
  • Sector
  • PRTC Health Care
  • FTRE Health Care
  • Exchange
  • PRTC Nasdaq
  • FTRE Nasdaq
  • Market Cap
  • PRTC 414.6M
  • FTRE 469.0M
  • IPO Year
  • PRTC N/A
  • FTRE N/A
  • Fundamental
  • Price
  • PRTC $16.78
  • FTRE $6.15
  • Analyst Decision
  • PRTC Buy
  • FTRE Hold
  • Analyst Count
  • PRTC 1
  • FTRE 11
  • Target Price
  • PRTC $45.00
  • FTRE $18.00
  • AVG Volume (30 Days)
  • PRTC 2.5K
  • FTRE 2.4M
  • Earning Date
  • PRTC 04-30-2025
  • FTRE 05-12-2025
  • Dividend Yield
  • PRTC N/A
  • FTRE N/A
  • EPS Growth
  • PRTC N/A
  • FTRE N/A
  • EPS
  • PRTC 0.21
  • FTRE N/A
  • Revenue
  • PRTC $4,828,000.00
  • FTRE $2,696,400,000.00
  • Revenue This Year
  • PRTC $35.98
  • FTRE N/A
  • Revenue Next Year
  • PRTC $115.38
  • FTRE $3.32
  • P/E Ratio
  • PRTC $7.47
  • FTRE N/A
  • Revenue Growth
  • PRTC 44.98
  • FTRE N/A
  • 52 Week Low
  • PRTC $13.30
  • FTRE $4.77
  • 52 Week High
  • PRTC $32.98
  • FTRE $37.24
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 45.09
  • FTRE 46.07
  • Support Level
  • PRTC $17.41
  • FTRE $5.40
  • Resistance Level
  • PRTC $17.55
  • FTRE $6.38
  • Average True Range (ATR)
  • PRTC 0.46
  • FTRE 0.45
  • MACD
  • PRTC 0.01
  • FTRE 0.21
  • Stochastic Oscillator
  • PRTC 40.40
  • FTRE 83.09

About PRTC PureTech Health plc

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

About FTRE Fortrea Holdings Inc.

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: